Académique Documents
Professionnel Documents
Culture Documents
Supported by sanofi-aventis
What is
quality of life?
Lesley Fallowfield
● Quality of life (QoL) is a ubiquitous concept that has different
BSc DPhil FMed Sci philosophical, political and health-related definitions.
Professor of Psycho-
oncology, Brighton &
Sussex Medical ● Health-related QoL (HRQoL) includes the physical,
School, University
functional, social and emotional well-being of an individual.
of Sussex
now often require QoL or patient-reported Systematic QoL assessments help delineate
outcome (PRO) information before licensing these side-effects and their temporal nature.
novel anticancer drugs and have issued This can assist in determining the types of
guidance as to which instruments can be supportive interventions that may be needed
used.4,5 (The Medicines and Healthcare to ameliorate the worst side-effects. For
products Regulatory Agency in the UK works example, hand and nail problems are
closely with both the FDA and EMEA). common with taxane therapy; however,
There are many ways in which research has shown that wearing specially
measurement of QoL can help improve designed frozen gloves during administration
patient care and outcomes (Box 2). of chemotherapy can prevent or minimise the
impact of this distressing side-effect.
The benefit:harm ratios of non-
Methods in which HRQoL pharmacological treatments such as intensity-
can improve patient care modulated radiotherapy or intraoperative
Widening the parameters of benefit radiotherapy may well reveal different side-
In many situations; for example, when effects from those found with external beam
chemotherapy is given for palliation in radiotherapy and therefore necessitate
advanced cancer, QoL is arguably the sole different ameliorative interventions.
criterion of efficacy. Conventional parameters
such as response, disease-free intervals and QoL as a prognostic indicator
survival may be less relevant. It is well known that patients with a good QoL
For example, survival in non-small cell at the start of treatment fare better than those
lung cancer may be only a few months and, with a poorer baseline score, but there is also
although meta-analyses have shown that an increasing body of literature in various
chemotherapy produces a modest extension cancers demonstrating the utility of QoL as an
of life compared with best supportive care, effective prognostic indicator.3 PROs have
some clinicians are reluctant to offer been shown to be stronger predictors of
chemotherapy as treatment side-effects may survival than computed tomography scans in
negate any survival gains. Clinical trials patients with liver metastases associated with
incorporating QoL assessments can provide colorectal cancer. In these patients,
more information and help clarify the relative assessment of QoL has been shown to provide
harms and benefits of palliative a better estimate of survival than
chemotherapy, and aid patient decisions measurement of tumour size.6 Given the
when survival gains are small. uncertainty and controversy that surrounds
Some treatment side-effects; for example, the use of expensive agents towards the end of
pain and emotional effects, can only be life which might be causing toxicity with only
determined by the patient. Physiological modest therapeutic gains, it would seem
measures and clinician-reported outcomes reasonable to use patients’ QoL to aid end-of-
often present a poor reflection of how a life treatment decisions. Finally, QoL could be
patient feels or indeed functions. Sometimes used as a surrogate endpoint for survival in
even the patients’ relatives and closest carers clinical trials.
are unable to offer accurate proxy judgements
about these QoL domains, although in some Decision-making
cases, when the patient may be too ill to Some novel therapies convey, at best, only
complete forms, there maybe no alternative. modest benefits that are outweighed by the
impact of side-effects; others may have
Indicating a need for supportive demonstrably better efficacy but a
interventions challenging side-effect profile. When
Therapies of proven efficacy almost always different treatment options are available
have unwanted side-effects which may be patients and doctors need to discuss these
severe enough for a doctor to reduce optimal potential harms and benefits. This is only
dosing schedules or for patients to stop really possible if there has been a systematic
adhering to the recommended dose. collection of such data using reliable PROs.
Occasionally QoL studies offer surprising or accrue from their provision are useful and
counter-intuitive information about the powerful arguments. Nausea and vomiting
impact of treatment on patients. An example (N&V) was previously one of the most
being the first randomised trial designed to debilitating and QoL-reducing side-effects of
determine the psychological benefits of chemotherapy. Drugs such as
breast-conserving surgery and radiotherapy metoclopramide were ineffective for many
compared with mastectomy. Surprisingly, patients, especially those on high-dose
breast-sparing operations did not convey regimens; indeed, N&V could become a dose-
psychosexual benefits, probably due to the limiting side-effect leading to some patients
fact that women still had to confront the fact abandoning treatment or developing
that they had a life-threatening disease.7 anticipatory N&V. The use of 5-
Patients are now often counselled and offered hydroxytriptamine 3 antagonists, such as
choice given that trials show no survival ondansetron, was initially restricted to only
advantage over the very different surgical those patients on the most emetogenic
policies and similar rates of psychological therapy due to their costs; however, QoL data
morbidity and sexual dysfunction.8 showed that the financial costs were small
In early breast cancer, additional adjuvant when considered alongside the patient
hormonal treatment for at least two years burden of unremitting N&V.11
reduces the risk of cancer recurrence and
death. Hormonal treatments have different
side-effect profiles and may affect a woman’s Design and development
choice of treatment. Anastrozole has fewer It is also important to consider how to
vasomotor complaints than are reported with measure HRQoL scientifically. Measurement
other aromatase inhibitors, but has some of PROs has recently become much more
disadvantages in terms of arthralgia, vaginal sophisticated. The development process is
dryness and sexual dysfunction.9 This type of now more structured and QoL tools are
comprehensive collection of PROs allows rigorously tested to ensure that they are
patients to make informed and individualised reliable, valid and responsive to change. The
decisions on the most appropriate treatment constructs and structure of the best
and any required supportive interventions. instruments, such as the generic short form
36 (SF-36),12 the European Organisation for
Resource allocation and healthcare Research and Treatment of Cancer (EORTC)
policy QLQ-C3013 and the Functional Assessment of
All healthcare systems have to confront the Chronic Illness Therapy (FACIT) system14 (Box
economic reality of a finite budget and 3), have been through years of development
infinite demands. Utility-based measures and modification. There are few reasons for
include the health utilities index (HUI) and developing any new tools, although
the popular EuroQoL (EQ-5D), which are refinement of existing resources and
used to generate quality-adjusted life- development of additional items, modules or
years (QALYs). QALYs are utilised by health subscales is needed if there is insufficient
economists to calculate the cost–utility of coverage of novel treatments or of the specific
different interventions. Policy makers may set disease being examined.
certain QALY thresholds. The use of these Oncology has produced the most
thresholds by regulatory bodies when making important disease-specific HRQoL tools. The
decisions regarding NHS payments for EORTC QLQ-C3013 and the Functional
treatments is controversial; indeed, QALYs Assessment of Cancer Therapy – General
have many limitations, including the (FACT-G)15 have both undergone an
undervaluing of life in old age and towards extraordinary amount of rigorous design,
the end of life (see What is a QALY?10 for development and validation, and testing as
further discussion). shown in Box 4.
Sometimes patients are denied supportive The best HRQoL systems have clearly
drug treatments on the grounds of cost, but if defined rules and procedures for the
QoL data are available, the benefits that development of additional items, ensuring a
Cancer-specific instruments
● EORTC QLQ-C30 with tumour-specific modules
● FACT-G with tumour and treatment-specific subscales
2. Psychologists conducted a structured interview with patients, which began with open-ended
prompt to report as many factors as possible which impact on QoL, followed by more focused
questions on different aspects of QoL.
3. Oncologists reviewed the patient-generated list and added any other items they felt necessary.
4. A group of 90 patients ranked the 137 items using a Likert scale (1 = little / no importance;
4 = very important) and only those rated ‘very’ or ‘extremely important’ were retained.
5. Oncologists, nurses and psychologists reviewed this list and eliminated any redundant items.
6. The final list of 38 items was reviewed to ensure reasonable content and coverage.
7. The final phase involved the piloting of different response modes and rewording of
ambiguous items.
burden of diseases, and differentiating the between the Information Resources Centre of
health benefits or harms of diverse the Mapi Research Institute, France and Dr
treatments. The respondent burden is not Marcello Tamburini, Institute Nazionale
great but an even shorter validated version, Tumori, Italy. The Quality of Life Instruments
the SF-12, comprised of 12 items, is also Database (QOLID) contains detailed
available. The instrument has been translated information on over 1,000 PRO
using backwards and forwards methodology questionnaires.
into approximately 50 languages.
What is
quality of life?